Weight.
The Weight program is designed for clinically supervised metabolic support and body composition goals. Your physician reviews your health profile and goals to determine whether a targeted protocol is appropriate.
Eligibility
Suitability is determined by your physician based on your medical history, current medications, and goals. Not appropriate for patients with certain endocrine, gastrointestinal, or pregnancy-related conditions.
Benefits you can feel.
The science behind it.
Modern weight management compounds act on incretin and metabolic pathways — including GLP-1, GIP, and glucagon receptors — to support appetite regulation, insulin sensitivity, and body composition under physician supervision.
Explore each compound.
Detailed reference for the compounds your physician may prescribe within this program.
Retatrutide
- What it is
- A next-generation triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The most advanced weight management compound currently in clinical development.
- What it does
- Produces significantly greater weight loss than dual or single receptor agonists. Phase 2 trials demonstrated up to 24% body weight reduction. Reduces appetite, improves metabolic rate, and addresses visceral fat accumulation. Glucagon receptor activity adds metabolic burn beyond GLP-1 alone.
- Who it is for
- Patients with significant weight management goals, metabolic syndrome, or those who have not achieved sufficient results with GLP-1 monotherapy. Physician assessment of suitability is mandatory.
- Format
- Lyophilised vial — subcutaneous injection. Weekly administration.
- Programme cycle
- 16-week minimum protocol with titration schedule. Physician review every 4 weeks.
Start with a consult
$99one-time
One-time telehealth consultation. Your physician will review your intake and determine whether a protocol is appropriate. Program is priced separately only if prescribed.